🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "major milestone" in the effort against drug-resistant strains of the bacteria, according to researchers.

An International Health Concern

Cases of gonorrhoea are on the rise worldwide, with figures suggesting more than 82 million infections per year. Particularly high rates are reported in Africa and nations within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of new treatments for gonorrhoea is an important and timely advancement in the context of rising global incidence, the spread of superbugs and the extremely scarce available drugs presently on offer.”

Health officials are increasingly worried about the surge in treatment-resistant strains. The global health body has classified it as a "critical concern". A tracking program showed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Gain Approval

One new antibiotic, marketed under the name a brand name, was approved by the US Food and Drug Administration in recent days for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers believe that specific application of this new drug will help hinder the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This medication, which is additionally indicated for urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP partnered with the drug firm Innoviva to bring it to fruition.

“This approval signifies a major breakthrough in the therapy of highly resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Testing Data and Global Access

As per results detailed in a major medical journal, the new drug eradicated more than 90% of genital gonorrhoea infections. This establishes an equal footing with the typical regimen, which involves an injection and a pill. The study included over 900 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the authority to license and sell the drug in many regions with limited resources.

Medical professionals directly involved have expressed hope. The availability of a easy-to-administer therapy such as this is hailed as a "game-changer" for gonorrhoea control. This is considered essential to reduce the burden of the illness for patients and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.